Dupilumab (Sanofi) cemented its position as the top-selling inflammatory illness medication with its first-in-class ... interaction and lowers eosinophil counts in severe asthma/EGPA. Benralizumab ...

WILMINGTON, DE — AstraZeneca has announced promising results from the BATURA Phase IIIb trial, showcasing the effectiveness of AIRSUPRA (albuterol/budesonide) in reducing the risk of severe ...

The China National Medical Products Association (NMPA) has approved AstraZeneca's Fasenra (benralizumab) as a maintenance treatment for individuals aged 12 years and older with severe eosinophilic ...

AstraZeneca is capping out-of-pocket costs for inhalers and related medication at no more than $35 per month, the drugmaker announced Monday. The Britain based pharma giant said the expanded ...

Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis Phase IIIb clinical development of Airsupra was conducted by Avillion under ...

Major pharmaceutical companies have agreed to cap out-of-pocket costs for some asthma patients at $35 per month, a move that offers relief but doesn't fully address the larger issue of high drug ...

Major pharmaceutical companies have agreed to cap out-of-pocket costs for some asthma patients at $35 per month, a move that offers relief but doesn't fully address the larger issue of high drug ...

Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA).

by Les Luchter, March 23, 2025 ; Teaming with the Professional Pickleball Association (PPA) in a multiyear deal, AstraZeneca’s seven-year-old Fasenra asthma medication has launched its first ...

AstraZeneca teams up with CSPC in a $1.92 billion deal to develop YS2302018, a novel Lp(a) disruptor aimed at treating cardiovascular disease. Airsupra, AstraZeneca's asthma drug, shows promise in ...

Major pharmaceutical companies have agreed to cap out-of-pocket costs for some asthma patients at $35 per month, a move that offers relief but doesn't fully address the larger issue of high drug ...

Major pharmaceutical companies have agreed to cap out-of-pocket costs for some asthma patients at $35 per month, a move that offers relief but doesn't fully address the larger issue of high drug ...